{"groups":[{"description":"Cisplatin: 40 mg/m2 IV (intravenously) weekly for 6 weeks\n\nIMRT 6 weeks: Intensity-modulated radiation therapy (IMRT), 30 fractions over 6 weeks, 5 fractions per week, 2 Gray per fraction to total dose of 60 Gy","id":"FG000","title":"IMRT 6 Weeks + Cisplatin"},{"description":"IMRT 5 weeks: Intensity-modulated radiation therapy (IMRT), 30 fractions over 5 weeks, 6 fractions per week, 2 Gray per fraction to total dose of 60 Gy","id":"FG001","title":"IMRT 5 Weeks"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}],"type":"Protocol Violation"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"158"},{"groupId":"FG001","numSubjects":"150"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"157"},{"groupId":"FG001","numSubjects":"149"}],"type":"Eligible"},{"achievements":[{"groupId":"FG000","numSubjects":"152"},{"groupId":"FG001","numSubjects":"147"}],"comment":"Randomized and eligible participants who started study treatment","type":"Started study treatment"},{"achievements":[{"groupId":"FG000","numSubjects":"58"},{"groupId":"FG001","numSubjects":"57"}],"comment":"Randomized and eligible with negative post-treatment positron emission tomography (PET) scan","type":"Negative post-treatment PET"},{"achievements":[{"groupId":"FG000","numSubjects":"157"},{"groupId":"FG001","numSubjects":"149"}],"comment":"Participants contributing data to results are considered to have completed the study","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"After first step registration and prior to randomization, patients were tested for p16. Only patients with p16-positive tumors continued on to randomization. In total, 316 patients were enrolled and 308 were randomized."}